NKTR
Income statement / Annual
Last year (2024), Nektar Therapeutics's total revenue was $98.43 M,
an increase of 9.22% from the previous year.
In 2024, Nektar Therapeutics's net income was -$118.96 M.
See Nektar Therapeutics,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$98.43 M |
$90.12 M |
$92.06 M |
$101.91 M |
$152.92 M |
$114.62 M |
$1.19 B |
$307.71 M |
$165.44 M |
$230.78 M |
| Cost of Revenue |
$30.69 M
|
$36.64 M
|
$21.64 M
|
$24.90 M
|
$19.48 M
|
$21.37 M
|
$24.41 M
|
$30.55 M
|
$30.22 M
|
$34.10 M
|
| Gross Profit |
$67.74 M
|
$53.48 M
|
$70.42 M
|
$77.01 M
|
$133.44 M
|
$93.24 M
|
$1.17 B
|
$277.16 M
|
$135.22 M
|
$196.68 M
|
| Gross Profit Ratio |
0.69
|
0.59
|
0.76
|
0.76
|
0.87
|
0.81
|
0.98
|
0.9
|
0.82
|
0.85
|
| Research and Development Expenses |
$120.91 M
|
$114.16 M
|
$218.32 M
|
$400.27 M
|
$408.68 M
|
$434.57 M
|
$399.54 M
|
$268.46 M
|
$203.80 M
|
$182.79 M
|
| General & Administrative Expenses |
$76.75 M
|
$77.42 M
|
$92.33 M
|
$122.84 M
|
$104.68 M
|
$98.71 M
|
$81.44 M
|
$52.36 M
|
$44.28 M
|
$43.27 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$76.75 M
|
$77.42 M
|
$92.33 M
|
$122.84 M
|
$104.68 M
|
$98.71 M
|
$81.44 M
|
$52.36 M
|
$44.28 M
|
$43.27 M
|
| Other Expenses |
-$24.72 M
|
-$676.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$172.94 M
|
$190.90 M
|
$310.66 M
|
$523.11 M
|
$513.36 M
|
$533.28 M
|
$480.98 M
|
$320.83 M
|
$248.08 M
|
$226.05 M
|
| Cost And Expenses |
$203.63 M
|
$227.55 M
|
$332.29 M
|
$548.01 M
|
$532.84 M
|
$554.65 M
|
$505.39 M
|
$351.37 M
|
$278.29 M
|
$260.16 M
|
| Interest Income |
$14.50 M
|
$19.01 M
|
$6.78 M
|
$2.73 M
|
$18.28 M
|
$46.34 M
|
$37.57 M
|
$4.52 M
|
$2.39 M
|
$1.68 M
|
| Interest Expense |
$28.11 M
|
$25.33 M
|
$28.91 M
|
$47.31 M
|
$37.12 M
|
$46.35 M
|
$42.78 M
|
$40.95 M
|
$42.18 M
|
$38.90 M
|
| Depreciation & Amortization |
$4.39 M
|
$7.82 M
|
$12.20 M
|
$14.15 M
|
$12.50 M
|
$11.00 M
|
$8.80 M
|
$12.60 M
|
$13.20 M
|
$12.86 M
|
| EBITDA |
-$86.70 M |
-$243.11 M |
-$323.87 M |
-$461.82 M |
-$394.33 M |
-$382.70 M |
$734.30 M |
-$42.52 M |
-$97.27 M |
-$29.37 M |
| EBITDA Ratio |
-0.88
|
-2.7
|
-3.52
|
-4.53
|
-2.58
|
-3.34
|
0.62
|
-0.14
|
-0.59
|
-0.13
|
| Operating Income Ratio |
-1.07
|
-1.52
|
-2.61
|
-4.38
|
-2.48
|
-3.84
|
0.58
|
-0.19
|
-0.68
|
-0.13
|
| Total Other Income/Expenses Net |
-$14.00 M
|
-$138.83 M
|
-$124.75 M
|
-$77.18 M
|
-$64.03 M
|
-$19.00 K
|
-$5.21 M
|
-$36.43 M
|
-$39.79 M
|
-$51.30 M
|
| Income Before Tax |
-$119.20 M
|
-$276.26 M
|
-$364.98 M
|
-$523.28 M
|
-$443.95 M
|
-$440.05 M
|
$682.73 M
|
-$96.08 M
|
-$152.65 M
|
-$80.67 M
|
| Income Before Tax Ratio |
-1.21
|
-3.07
|
-3.96
|
-5.13
|
-2.9
|
-3.84
|
0.57
|
-0.31
|
-0.92
|
-0.35
|
| Income Tax Expense |
-$239.00 K
|
-$200.00 K
|
$3.22 M
|
$557.00 K
|
$493.00 K
|
$613.00 K
|
$1.41 M
|
$616.00 K
|
$876.00 K
|
$506.00 K
|
| Net Income |
-$118.96 M
|
-$276.06 M
|
-$368.20 M
|
-$523.84 M
|
-$444.44 M
|
-$440.67 M
|
$681.31 M
|
-$96.69 M
|
-$153.52 M
|
-$81.18 M
|
| Net Income Ratio |
-1.21
|
-3.06
|
-4
|
-5.14
|
-2.91
|
-3.84
|
0.57
|
-0.31
|
-0.93
|
-0.35
|
| EPS |
-8.68 |
-21.79 |
-29.51 |
-42.9 |
-37.33 |
-37.8 |
56.7 |
-9.3 |
-16.5 |
-9.15 |
| EPS Diluted |
-8.68 |
-21.79 |
-29.51 |
-42.9 |
-37.33 |
-37.8 |
56.7 |
-9.3 |
-16.5 |
-9.15 |
| Weighted Average Shares Out |
$13.71 M
|
$12.67 M
|
$12.48 M
|
$12.22 M
|
$11.91 M
|
$11.67 M
|
$12.01 M
|
$10.40 M
|
$9.30 M
|
$8.83 M
|
| Weighted Average Shares Out Diluted |
$13.71 M
|
$12.67 M
|
$12.48 M
|
$12.22 M
|
$11.91 M
|
$11.67 M
|
$12.01 M
|
$10.40 M
|
$9.31 M
|
$8.83 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
